Post hoc analysis: alirocumab benefits HeFH and T3HLP patients Results from the German MILOS cohort demonstrate real-world effectiveness and safety of bempedoic acid PCSK9 inhibitors are unlikely to contribute to mood disorders PCSK9 inhibitors may be effective treatment for PAD PACMAN-AMI: new data on lesion-level effects of lipid lowering AT-TARGET-IT shows reduced CV risk with early PCSK9i in ACS

Become a member

Register

You will need to be a member to access full content on PCSK9 Forum.

Membership is free and provides full access to all content on the website. Please tick the box below to ensure you receive all email alerts and newsletters.

PCSK9 Forum is intended for healthcare professionals.

Registration Options

Create Profile

First Name *

Last Name *

Email Address *

Username (lowercase alphanumeric) *

Password (type this twice please) *

password strength indicator

Additional Info

Newsletters and Email updates

I'd like to receive e-mail updates from PCSK9 Forum

Other information

Country *

Speciality *

Security Verification

Complete Registration

About PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is a not-for-profit organisation established by leading researchers in the fields of atherosclerosis, lipids and cardiovascular disease. Our mission is to raise awareness and knowledge of the significant role played by PCSK9 in lipid metabolism and its value as a novel therapeutic target.

Editorial Policy

Unless otherwise indicated, opinions expressed in the PCSK9 Education and Research Forum are those of the contributors. All patients should discuss their medication with their healthcare professional. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the PCSK9 Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.

Educational Partners and Supporters

Become a member

Membership Login

Register

About PCSK9 Education and Research Forum

Editorial Policy